Abstract 618P
Background
Renal Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) among adults is an extremely rare malignancy. Accurate diagnosis mandates detailed immunohistochemistry (IHC) and molecular characterization. There is limited data on the treatment of these patients. We present a clinicopathological and molecular profile of renal ES/PNET from a single South Indian tertiary referral center.
Methods
We conducted a retrospective study of adults with a histopathological diagnosis of renal ES/PNET treated at our center over the last 20 years. All patients had received a standard treatment protocol of VAC/IE. Principal outcomes were event-free survival (EFS), overall survival (OS) and adverse events during treatment.
Results
We included 25 patients with renal ES treated at our center from 2003-2023. 68% were male, with median age 29(18-53). 8(32%) had localised disease and 17(68%) had recurrent/metastatic disease; lung(36%) and bone(28%) were the common sites of metastases. Median tumour size was 13.5cm and renal vein/IVC thrombus was present in 11(55%) patients. IHC(done in 24 patients), showed CD99 +, NKX 2.2 + in 100% and FLI1 + in 93.7%. RT-PCR/FISH done in 15 patients revealed EWS-FLI1 translocations in 5 patients, 4 of which were Type 1. Nephrectomy was performed in 19 patients: 8 radical for non-metastatic and 11 palliative for metastatic disease. 16 received systemic therapy, the median number of cycles being 10(Range:2-16). 11 patients received concurrent radiation. Grade 3/4 anaemia, thrombocytopenia, neutropenia, and febrile neutropenia was seen in 1(6.6%),1(6.6%),8(50%) and 8(50%) patients respectively during VAC/IE. Only 50% of patients had long term follow up. Survival at 3 years is 64.3%(83% for localised disease, 57.3% for recurrent/metastatic).
Conclusions
This study represents a substantial cohort of adult patients with renal ES/PNET undergoing a unified treatment approach. Predominantly, tumors presented as extensive and locally aggressive with favourable survival for localised disease. While these observations offer valuable insights, the rarity of the disease underscores the need for larger, multicentric studies for more definitive conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract